Clinical Trial Detail

NCT ID NCT02094872
Title Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Yale University
Indications

melanoma

Therapies

Doxorubicin

Age Groups: adult

Additional content available in CKB BOOST